BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19287456)

  • 21. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
    Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
    J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D1 in breast cancer.
    Barnes DM; Gillett CE
    Breast Cancer Res Treat; 1998; 52(1-3):1-15. PubMed ID: 10066068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
    Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
    Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism.
    Carrère N; Belaud-Rotureau MA; Dubus P; Parrens M; de Mascarel A; Merlio JP
    Haematologica; 2005 Jun; 90(6):854-6. PubMed ID: 15951302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model.
    Wei M; Zhu L; Li Y; Chen W; Han B; Wang Z; He J; Yao H; Yang Z; Zhang Q; Liu B; Gu Q; Zhu Z; Shen K
    Cancer Sci; 2011 Aug; 102(8):1537-44. PubMed ID: 21521417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Female-specific rectal carcinogenesis in cyclin D1b transgenic mice.
    Kim CJ; Tambe Y; Mukaisho K; Sugihara H; Isono T; Sonoda H; Shimizu T; Kondoh G; Inoue H
    Carcinogenesis; 2014 Jan; 35(1):227-36. PubMed ID: 23975835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.
    Lu F; Gladden AB; Diehl JA
    Cancer Res; 2003 Nov; 63(21):7056-61. PubMed ID: 14612495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
    Kim CJ; Terado T; Tambe Y; Mukaisho KI; Sugihara H; Kawauchi A; Inoue H
    Int J Oncol; 2018 Jan; 52(1):231-240. PubMed ID: 29115414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin D1b Splice Variant Promotes αvβ3-mediated EMT Induced by LPS in Breast Cancer Cells.
    Luo BP; Luo J; Hu YB; Yao XW; Wu FH
    Curr Med Sci; 2018 Jun; 38(3):467-472. PubMed ID: 30074214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
    Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
    Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b.
    Meng H; Tian L; Zhou J; Li Z; Jiao X; Li WW; Plomann M; Xu Z; Lisanti MP; Wang C; Pestell RG
    Cell Cycle; 2011 Jan; 10(1):73-81. PubMed ID: 21200149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCND1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in Chinese population.
    Wang N; Qian X; Wang S; Gao H; Wang L; Huo Y; Zhang S
    Mol Carcinog; 2012 Feb; 51(2):196-205. PubMed ID: 21594903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions.
    Shoker BS; Jarvis C; Davies MP; Iqbal M; Sibson DR; Sloane JP
    Br J Cancer; 2001 Apr; 84(8):1064-9. PubMed ID: 11308255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin D1: polymorphism, aberrant splicing and cancer risk.
    Knudsen KE; Diehl JA; Haiman CA; Knudsen ES
    Oncogene; 2006 Mar; 25(11):1620-8. PubMed ID: 16550162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular markers in Paget disease of the breast.
    Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
    J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.